Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Major Depressive Episodes Associated With Bipolar I Disorder

NCT07494305 is registered in ClinicalTrials.gov with LB Pharmaceuticals Inc. as lead sponsor.

NCT NCT07494305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07494305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Major Depressive Episodes Associated With Bipolar I Disorder
Lead sponsor
LB Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
January 23, 2026
Completion date
February 29, 2028
Enrollment
320 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder